Clinical medicine profile
Testosterone Propionate / Testosterone Phenylpropionate / Testosterone Isocaproate / Testosterone Decanoate
Therapeutic agent (verify pharmacological class)
- Route
- See product SmPC
- Schedule
- POM
- ATC
- Not assigned
- PPB status
- registered
This profile needs source confirmation
Some sections contain general class guidance rather than medicine-specific evidence. Confirm prescribing decisions against the current SmPC and Kenya STG/EML.
Safety essentials
The information most likely to change a prescribing or dispensing decision.
Contraindications
- [From component Testosterone] CONTRAINDICATIONS Androgens are contraindicated in men with carcinomas of the breast or with known or suspected carcinomas of the prostate.
- If administered to pregnant women, androgens cause virilization of the external genitalia of the female fetus.
- The virilization includes clitoromegaly, abnormal vaginal development, and fusion of genital folds to form a scrotal-like structure.
- The degree of masculinization is related to the amount of drug given and the age of the fetus, and is most likely to occur in the female fetus when the drugs are given in the first trimester.
- If the patient becomes pregnant while taking these drugs she should be apprised of the potential hazard to the fetus.
Precautions
- [From component Testosterone] WARNINGS In patients with breast cancer, androgen therapy may cause hypercalcemia by stimulating osteolysis.
- In this case, the drug should be discontinued.
- Prolonged use of high doses of androgens has been associated with the development of peliosis hepatis and hepatic neoplasms including hepatocellular carcinoma (see PRECAUTIONS - Carcinogenesis, Mutagenesis, Impairment of Fertility).
- Peliosis hepatis can be a life-threatening or fatal complication.
- Men treated with androgens may be at an increased risk for the development of prostatic hypertrophy and prostatic carcinoma.
- There have been postmarketing reports of venous thromboembolic events, including deep vein thrombosis (DVT) and pulmonary embolism (PE), in patients using testosterone products, such as TESTOPEL ® (testosterone pellets).
- Evaluate patients who report symptoms of pain, edema, warmth and erythema in the lower extremity for DVT and those who present with acute shortness of breath for PE.
- If a venous thromboembolic event is suspected, discontinue treatment with TESTOPEL ® (testosterone pellets) and initiate appropriate workup and management (see ADVERSE REACTIONS ).
- Long term clinical safety trials have not been conducted to assess the cardiovascular outcomes of testosterone replacement therapy in men.
- To date, epidemiologic studies and randomized controlled trials have been inconclusive for determining the risk of major adverse cardiovascular events (MACE), such as non-fatal myocardial infarction, non-fatal stroke, and cardiovascular death, with the use of testosterone compared to non-use.
- Some studies, but not all, have reported an increased risk of MACE in association with use of testosterone replacement therapy in men.
- Patients should be informed of this possible risk when deciding whether to use or to continue to use TESTOPEL ® (testosterone pellets).
Dosing matrix
Population and organ-function guidance, shown together for faster comparison.
Dosing is indication-, age-, weight- and organ-function-specific for this INN. Do not use class averages for high-risk patients. Confirm the exact regimen in the current SmPC and Kenya Standard Treatment Guidelines. Typical professional workflow: (1) confirm indication, (2) check renal/hepatic function, (3) screen interactions/allergies, (4) select dose/route/duration, (5) define monitoring.
Paediatric dosing is weight- and age-based; use a paediatric formulary / SmPC. Do not extrapolate adult tablets without calculation.
Review renal impairment dosing; many agents need CrCl/eGFR adjustment.
- CrCl 0–120: Confirm renal dosing in product SmPC / primary label.
Review hepatic impairment dosing; monitor LFTs if agent is hepatically cleared or hepatotoxic.
Use, effects & interactions
Indications
- Therapeutic use is agent- and indication-specific within the class (Therapeutic agent (verify pharmacological class)).
- Use according to culture results, national guidelines (Kenya STG/EML where applicable) and the current product SmPC.
- Androgen deficiency
Adverse effects
- [From component Testosterone] ADVERSE REACTIONS The following adverse reactions have been identified during post-approval use of testosterone replacement therapy, including TESTOPEL ® .
- Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
- Implantation Site Infection and Pellet Extrusion: (see WARNINGS) Endocrine and Urogenital, Male.
- Gynecomastia and excessive frequency and duration of penile erections.
- Oligospermia may occur at high dosages (see CLINICAL PHARMACOLOGY ).
- Skin and Appendages.
- Hirsutism, male pattern of baldness, and acne.
- Cardiovascular Disorders.
- Myocardial infarction, stroke.
- Fluid and Electrolyte Disturbances.
- Retention of sodium, chloride, water, potassium, calcium and inorganic phosphates.
- Gastrointestinal.
- Nausea, cholestatic jaundice, alterations in liver function tests, rarely hepatocellular neoplasms and peliosis hepatis (see WARNINGS ).
- Hematologic.
Drug interactions
Open multi-drug checker ↗- A mixture of testosterone esters with a long duration of action
- Fixed-dose/multi-ingredient product.
- Clinical details partially inherited from component monographs: Testosterone, Testosterone, Testosterone, Testosterone.
- Confirm combination SmPC for exact dosing.
Mechanism & disposition
Testosterone replacement therapy.
Read complete mechanism
Testosterone replacement therapy. A mixture of testosterone esters with a long duration of action Mechanism is agent-specific. At receptor, enzyme, ion channel, transporter or microbial target level, the drug alters a physiological or pathological pathway to produce its therapeutic effect. Confirm precise molecular mechanism in current SmPC / pharmacology reference for this INN before high-stakes decisions.
Product-specific
Product-specific
See product SmPC
are product-specific. Consider food effects, protein binding, hepatic CYP/UGT
when adjusting for organ impairment, age and drug interactions. Verify parameters in the current SmPC.
Pregnancy, lactation & diet
[Testosterone Propionate] Use only if potential benefit justifies potential risk; prefer agents with better reproductive data when alternatives exist. [Testosterone Phenylpropionate] Use only if potential benefit justifies potential risk; prefer agents with better reproductive data when alternatives exist. [Testosterone Isocaproate] Use only if potential benefit justifies potential risk; prefer agents with better reproductive data when alternatives exist.
[Testosterone Propionate] Assess infant risk vs benefit of maternal therapy; prefer agents with lactation data. [Testosterone Phenylpropionate] Assess infant risk vs benefit of maternal therapy; prefer agents with lactation data. [Testosterone Isocaproate] Assess infant risk vs benefit of maternal therapy; prefer agents with lactation data.
Brands & loaded prices
| Brand | Manufacturer | Pack | Observed price |
|---|---|---|---|
| No reviewed brand listings are linked yet. | |||
Sources & review state
Decision support only. Confirm patient-specific decisions against the current product SmPC, Kenya STG/EML, and professional judgement.